Cargando…

Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia

Most acute myeloid leukemia (AML) cells are argininosuccinate synthetase‐deficient. Pegylated arginine deiminase (ADI‐PEG20) monotherapy depletes circulating arginine, thereby selectively inducing tumor cell death. ADI‐PEG20 was shown to induce complete responses in ~10% of relapsed/refractory or po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsai, Hui‐Jen, Hsiao, Hui‐Hua, Hsu, Ya‐Ting, Liu, Yi‐Chang, Kao, Hsiao‐Wen, Liu, Ta‐Chih, Cho, Shih‐Feng, Feng, Xiaoxing, Johnston, Amanda, Bomalaski, John S., Kuo, Ming‐Chung, Chen, Tsai‐Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085967/ https://www.ncbi.nlm.nih.gov/pubmed/33787078 http://dx.doi.org/10.1002/cam4.3871

Ejemplares similares

A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients
por: Tsai, Hui-Jen, et al.
Publicado: (2017)

Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors
por: Yao, Shuyang, et al.
Publicado: (2021)

Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers
por: Chang, Kwang-Yu, et al.
Publicado: (2021)

Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment
por: Rogers, Leonard C., et al.
Publicado: (2023)

Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM
por: Przystal, Justyna Magdalena, et al.
Publicado: (2018)

A Phase 1 study of ADI‐PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1‐negative metastatic uveal melanoma
por: Chan, Pui Ying, et al.
Publicado: (2022)

Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies
por: Yao, Shuyang, et al.
Publicado: (2021)

A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma
por: Phillips, Melissa M., et al.
Publicado: (2023)

Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma
por: Phillips, Melissa M., et al.
Publicado: (2023)

WWOX-rs13338697 genotype predicts therapeutic efficacy of ADI-PEG 20 for patients with advanced hepatocellular carcinoma
por: Chu, Yu-De, et al.
Publicado: (2022)

Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20)
por: Burrows, Natalie, et al.
Publicado: (2016)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Decreased argininosuccinate synthetase expression in Thai patients with cholangiocarcinoma and the effects of ADI-PEG20 treatment in CCA cell lines
por: Roeksomtawin, Somphon, et al.
Publicado: (2018)

The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia
por: Liu, Chia‐Jen, et al.
Publicado: (2020)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients
por: Yang, T-S, et al.
Publicado: (2010)

Role of CD19 and specific KIT‐D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities
por: Wang, Biao, et al.
Publicado: (2020)

Adi Armoni
por: Armoni, Adi
Publicado: (2022)

Adie's Syndrome
por: Marmion, Vincent
Publicado: (1975)

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
por: Konopleva, Marina Y., et al.
Publicado: (2022)

Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer
por: Szlosarek, Peter W., et al.
Publicado: (2021)

Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan
por: Tsai, Yu-Fen, et al.
Publicado: (2018)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

The ADI model problem
por: Wachspress, Eugene
Publicado: (2013)

Adie’s Tonic Pupil
por: Kanzaria, Hemal K, et al.
Publicado: (2012)

Pupila de Adie
por: Babiano Fernandez, Miguel Angel
Publicado: (2020)

Idarubicin Plus Behenoyl Cytarabine and 6-thioguanine Compares Favorably with Idarubicin Plus Cytarabine-based Regimen for Children with Previously Untreated Acute Myeloid Leukemia: 10-Year Retrospective, Multicenter Study in Korea
por: Lee, Dae Hyoung, et al.
Publicado: (2010)

Suppression of oral cancer by induction of cell cycle arrest and apoptosis using Juniperus communis extract
por: Lee, Ching-Chang, et al.
Publicado: (2020)

Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
por: Ferrara, Felicetto
Publicado: (2020)

Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation
por: Gill, Harinder, et al.
Publicado: (2020)

Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase
por: Kelly, M P, et al.
Publicado: (2012)

Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists
por: Relias, Valerie, et al.
Publicado: (2020)

Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy
por: Yamauchi, Takahiro, et al.
Publicado: (2021)

Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
por: Patzke, Ciera L., et al.
Publicado: (2020)

Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia
por: Zhou, Shiyong, et al.
Publicado: (2017)

Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia
por: Wei, Hui, et al.
Publicado: (2020)

PEG3 mutation is associated with elevated tumor mutation burden and poor prognosis in breast cancer
por: Zhang, Min, et al.
Publicado: (2020)

Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase‐3‐mediated cleavage of the AML1‐ETO oncoprotein
por: Cao, Jiang, et al.
Publicado: (2016)

Leukemic Phase of CD5+ Diffuse Large B-Cell Lymphoma
por: Hsiao, Hui-Hua, et al.
Publicado: (2018)

Ultrasonography‐driven combination antibiotic therapy with tigecycline significantly increases survival among patients with neutropenic enterocolitis following cytarabine‐containing chemotherapy for the remission induction of acute myeloid leukemia
por: Pugliese, Novella, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tua4l399rsvdriavgssg0p95qf